Islet transplantation has proven to be an effective treatment for type 1 diabetes (T1D) yet is hampered by the shortage of available tissue. Recently, two reports from a Viacyte multicenter clinical trial demonstrate the feasibility, safety, and potential efficacy of transplanting macro-encapsulated human stem cell-derived pancreatic endoderm cells into patients with T1D, highlighting the promise of a stem cell-based therapeutic approach.
Journal article
2022-02-01T00:00:00+00:00
34
193 - 196
3
Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado Anschutz Medical Campus, 1775 Aurora Court, Aurora, CO 80045, USA.
Stem Cells, Endoderm, Humans, Diabetes Mellitus, Type 1, Islets of Langerhans Transplantation, Cell Differentiation